Stoke Therapeutics (STOK) late Wednesday filed a registration statement with the US Securities and Exchange Commission for the potential sale of up to $400 million of securities from time to time.
The filing covers common and preferred shares, debt securities, warrants, subscription rights, and units.
Net proceeds are intended for general corporate purposes, the company said.